These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29854250)

  • 1. Towards precision informatics of pharmacovigilance: OAE-CTCAE mapping and OAE-based representation and analysis of adverse events in patients treated with cancer drugs.
    Wong MU; Racz R; Ong E; He Y
    AMIA Annu Symp Proc; 2017; 2017():1793-1801. PubMed ID: 29854250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ODAE: Ontology-based systematic representation and analysis of drug adverse events and its usage in study of adverse events given different patient age and disease conditions.
    Yu H; Nysak S; Garg N; Ong E; Ye X; Zhang X; He Y
    BMC Bioinformatics; 2019 May; 20(Suppl 7):199. PubMed ID: 31074377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ontology-Based Vaccine Adverse Event Representation and Analysis.
    Xie J; He Y
    Adv Exp Med Biol; 2017; 1028():89-103. PubMed ID: 29058218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
    J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
    McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
    Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ontology-based Vaccine and Drug Adverse Event Representation and Theory-guided Systematic Causal Network Analysis toward Integrative Pharmacovigilance Research.
    He Y
    Curr Pharmacol Rep; 2016 Jun; 2(3):113-128. PubMed ID: 27458549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Hay JL; Atkinson TM; Reeve BB; Mitchell SA; Mendoza TR; Willis G; Minasian LM; Clauser SB; Denicoff A; O'Mara A; Chen A; Bennett AV; Paul DB; Gagne J; Rogak L; Sit L; Viswanath V; Schrag D; Basch E;
    Qual Life Res; 2014 Feb; 23(1):257-69. PubMed ID: 23868457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OntoADR a semantic resource describing adverse drug reactions to support searching, coding, and information retrieval.
    Souvignet J; Declerck G; Asfari H; Jaulent MC; Bousquet C
    J Biomed Inform; 2016 Oct; 63():100-107. PubMed ID: 27369567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linking MedDRA(®)-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors.
    Sarntivijai S; Zhang S; Jagannathan DG; Zaman S; Burkhart KK; Omenn GS; He Y; Athey BD; Abernethy DR
    Drug Saf; 2016 Jul; 39(7):697-707. PubMed ID: 27003817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.
    Reeve BB; McFatrich M; Pinheiro LC; Weaver MS; Sung L; Withycombe JS; Baker JN; Mack JW; Waldron MK; Gibson D; Tomlinson D; Freyer DR; Mowbray C; Jacobs S; Palma D; Martens CE; Gold SH; Jackson KD; Hinds PS
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27650708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semantic categories and relations for modelling adverse drug reactions towards a categorial structure for pharmacovigilance.
    Bousquet C; Trombert B; Kumar A; Rodrigues JM
    AMIA Annu Symp Proc; 2008 Nov; 2008():61-5. PubMed ID: 18998982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OAE: The Ontology of Adverse Events.
    He Y; Sarntivijai S; Lin Y; Xiang Z; Guo A; Zhang S; Jagannathan D; Toldo L; Tao C; Smith B
    J Biomed Semantics; 2014; 5():29. PubMed ID: 25093068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Kluetz PG; Chingos DT; Basch EM; Mitchell SA
    Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
    Basch E; Reeve BB; Mitchell SA; Clauser SB; Minasian LM; Dueck AC; Mendoza TR; Hay J; Atkinson TM; Abernethy AP; Bruner DW; Cleeland CS; Sloan JA; Chilukuri R; Baumgartner P; Denicoff A; St Germain D; O'Mara AM; Chen A; Kelaghan J; Bennett AV; Sit L; Rogak L; Barz A; Paul DB; Schrag D
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25265940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leveraging graph topology and semantic context for pharmacovigilance through twitter-streams.
    Eshleman R; Singh R
    BMC Bioinformatics; 2016 Oct; 17(Suppl 13):335. PubMed ID: 27766937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ontology-based systematical representation and drug class effect analysis of package insert-reported adverse events associated with cardiovascular drugs used in China.
    Wang L; Li M; Xie J; Cao Y; Liu H; He Y
    Sci Rep; 2017 Oct; 7(1):13819. PubMed ID: 29061976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ontology-based systematic representation and analysis of traditional Chinese drugs against rheumatism.
    Liu Q; Wang J; Zhu Y; He Y
    BMC Syst Biol; 2017 Dec; 11(Suppl 7):130. PubMed ID: 29322929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
    Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
    Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bæksted C; Nissen A; Pappot H; Bidstrup PE; Mitchell SA; Basch E; Dalton SO; Johansen C
    J Pain Symptom Manage; 2016 Aug; 52(2):292-7. PubMed ID: 27090851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.
    Shepshelovich D; McDonald K; Spreafico A; Razak ARA; Bedard PL; Siu LL; Minasian L; Hansen AR
    Oncologist; 2019 Apr; 24(4):e146-e148. PubMed ID: 30728278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.